757 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target? http://www.zacks.com/stock/news/188645/biotech-stock-roundup-amgen-in-the-news-ariad-a-takeover-target?cid=CS-ZC-FT-188645 Sep 02, 2015 - ARIAD's (ARIA) shares shot up on acquisition rumors; Amgen (AMGN) gained FDA approval for its potential blockbuster treatment, Repatha.
Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor http://www.zacks.com/stock/news/188389/alnylam-presents-positive-data-on-pcsk9-synthesis-inhibitor?cid=CS-ZC-FT-188389 Aug 31, 2015 - Alnylam (ALNY) and The Medicines Company (MDCO) presented initial data from their ongoing phase I study on ALN-PCSsc for the treatment of hypercholesterolemia.
Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S. http://www.zacks.com/stock/news/188143/amgens-pcsk9-inhibitor-repatha-approved-in-the-us?cid=CS-ZC-FT-188143 Aug 28, 2015 - Will FDA approval of Amgen's (AMGN) Repatha trigger a pricing war for this class of treatment?
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure http://www.zacks.com/stock/news/187958/the-zacks-analyst-blog-highlights-vital-therapies-amgen-biomarin-acorda-and-macrocure?cid=CS-ZC-FT-187958 Aug 27, 2015 - The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data http://www.zacks.com/stock/news/187762/biotech-stock-roundup-acorda-gains-on-patent-issues-vital-crushed-by-liver-data?cid=CS-ZC-FT-187762 Aug 26, 2015 - It was a mixed week for the biotech sector with companies like Acorda (ACOR) and BioMarin (BMRN) providing positive updates while others saw their share prices crashing on disappointing data.
Bull of the Day: Regeneron Pharma (REGN) http://www.zacks.com/commentary/53223/bull-of-the-day-regeneron-pharma-regn?cid=CS-ZC--53223 Aug 12, 2015 - Bull of the Day: Regeneron Pharma (REGN)
Earnings Growth Hard to Come By http://www.zacks.com/commentary/51912/earnings-growth-hard-to-come-by?cid=CS-ZC--51912 Jul 24, 2015 - Earnings Growth Hard to Come By

Pages: 1...717273747576

<<<Page 76